focus
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.
The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.
advertisement
Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Fetal surgery at risk from Dobbs and new abortion restrictions
Next article： Peter Hotez and the public health issue of online harassment
Next article： Peter Hotez and the public health issue of online harassment
